Table 4 Survival analysis of clinicopathologic variables for overall survival (OS) and progression-free survival (PFS) in the paediatric group.
Variable | One-year | Five-year | One-year | Five-year | P-value | |
|---|---|---|---|---|---|---|
OS | OS | PFS | PFS | Log-rank test | ||
% (SE) | % (SE) | % (SE) | % (SE) | OS | PFS | |
Sex | 0.32 | 0.36 | ||||
Male | 100 | 66.7 (0.27) | 60 (0.22) | 60 (0.22) | ||
Female | 100 | 100 | 85.7 (0.13) | 85.7 (0.13) | ||
Symptom | —* | —* | ||||
Symptomless | 100 | — | 100 | — | ||
Haematuria | 100 | 75.0 (0.22) | 80 (0.18) | 80 (0.18) | ||
Abdominal mass | —* | — | — | — | ||
Flank pain | 100 | — | 100 | — | ||
Laterality | 0.16 | 0.13 | ||||
Left | 100 | 100 | 100 | 100 | ||
Right | 100 | 50.0 (0.35) | 57.1 (0.19) | 57.1 (0.19) | ||
Operation | — | — | ||||
RN | 100 | 83.3 (0.15) | 74.1 (0.13) | 74.1 (0.13) | ||
NSS | — | — | — | — | ||
pT stage | 0.32 | 0.24 | ||||
T1/T2 | 100 | 100 | 87.5 (0.12) | 87.5 (0.12) | ||
T3/T4 | 100 | 66.7 (0.27) | 50.0 (0.25) | 50.0 (0.25) | ||
Nuclear grade | 0.48 | 0.73 | ||||
1/2 | 100 | 75.0 (0.22) | 76.2 (0.15) | 76.2 (0.15) | ||
3/4 | 100 | 100 | 66.7 (0.27) | 66.7 (0.27) | ||
AJCC stage | 0.48 | 0.27 | ||||
I/II | 100 | 100 | 100 | 100 | ||
III/IV | 100 | 75.0 (0.22) | 64.8 (0.17) | 64.8 (0.17) | ||
Local lymph node metastasis | 0.48 | 0.27 | ||||
LN+ | 100 | 75.0 (0.22) | 64.8 (0.17) | 64.8 (0.17) | ||
LN− | 100 | 100 | 100 | 100 | ||
Vena cava tumour thrombosis | 0.66 | 0.58 | ||||
Positive | 100 | 100 | 100 | 100 | ||
Negative | 100 | 80.0 (0.18) | 71.6 (0.14) | 71.6 (0.14) | ||
Adjuvant therapy | — | — | ||||
None | 100 | 83.3 (0.15) | 88.9 (0.11) | 88.9 (0.11) | ||
Immunotherapy | — | — | — | — | ||
Targeted therapy | — | — | — | — | ||
Tumour boundary | 0.32 | 0.21 | ||||
Clear | 100 | 100 | 100 | 100 | ||
Unclear | 100 | 66.7 (0.27) | 62.5 (0.17) | 62.5 (0.17) | ||
